Patents Assigned to TMRC
-
Publication number: 20200061007Abstract: The present invention aims to provide a growth inhibitor for cancer stem cells resistant to existing anticancer drug therapies, which growth inhibitor acts on the cells through growth inhibition and apoptosis. The growth inhibitor for cancer stem cells contains a retinoid agonist, preferably tamibarotene, alone or in combination with a rexinoid agonist, preferably bexarotene, as an effective component(s). The growth inhibitor for cancer stem cells enhances the effects of various anticancer drugs when the growth inhibitor is used in combination with the anticancer drugs.Type: ApplicationFiled: November 4, 2019Publication date: February 27, 2020Applicants: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY, TMRC Co., Ltd.Inventors: Akira KURISAKI, Ying Ying WANG, Hitomi TAKADA, Hisao EKIMOTO
-
Publication number: 20170079942Abstract: The present invention aims to provide a growth inhibitor for cancer stem cells resistant to existing anticancer drug therapies, which growth inhibitor acts on the cells through growth inhibition and apoptosis. The growth inhibitor for cancer stem cells contains a retinoid agonist, preferably tamibarotene, alone or in combination with a rexinoid agonist, preferably bexarotene, as an effective component(s). The growth inhibitor for cancer stem cells enhances the effects of various anticancer drugs when the growth inhibitor is used in combination with the anticancer drugs.Type: ApplicationFiled: May 20, 2015Publication date: March 23, 2017Applicants: NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY, TMRC Co., Ltd.Inventors: Akira KURISAKI, Ying Ying WANG, Hitomi TAKADA, Hisao EKIMOTO
-
Publication number: 20120277295Abstract: To provide a kit for cancer treatment and a pharmaceutical composition for cancer treatment that can inhibit the growth of tumors and cancers in mammals more than ever. The kit for cancer treatment includes a combination of two different drugs in a kit formulation. The first drug contains a synthetic retinoid or a pharmaceutically acceptable organic or inorganic acid addition salt thereof, and the second drug contains a chemotherapeutic agent for cancer treatment. A synthetic retinoid that can be suitably used is a benzoic acid derivative represented by the following formula (I): or a pharmaceutically acceptable organic or inorganic acid addition salt thereof.Type: ApplicationFiled: July 12, 2012Publication date: November 1, 2012Applicant: TMRC Co., Ltd.Inventor: Hisao EKIMOTO
-
Patent number: 8252837Abstract: The present invention provides a practical preparation form of Tamibarotene and dosage form thereof, which exhibit high absorptivity by the body with minimized toxicity, and which are safe and stable without any risk of contamination. It is provided a Tamibarotene capsule preparation which encapsulates a composition comprising an oil component as its base and Tamibarotene as an active ingredient dissolved in the base. It is preferred that the oil component be propylene glycol fatty acid esters or polyethylene glycols. It is also preferred that the Tamibarotene capsule preparation comprise 0.1-50 mg/mL of the Tamibarotene based on the oil component.Type: GrantFiled: March 28, 2008Date of Patent: August 28, 2012Assignee: TMRC Co., Ltd.Inventor: Hisao Ekimoto
-
Publication number: 20090117203Abstract: To provide a kit for cancer treatment and a pharmaceutical composition for cancer treatment that can inhibit the growth of tumors and cancers in mammals more than ever. The kit for cancer treatment includes a combination of two different drugs in a kit formulation. The first drug contains a synthetic retinoid or a pharmaceutically acceptable organic or inorganic acid addition salt thereof, and the second drug contains a chemotherapeutic agent for cancer treatment. A synthetic retinoid that can be suitably used is a benzoic acid derivative represented by the following formula (I): or a pharmaceutically acceptable organic or inorganic acid addition salt thereof.Type: ApplicationFiled: February 22, 2007Publication date: May 7, 2009Applicant: TMRC Co., Ltd.Inventor: Hisao Ekimoto
-
Publication number: 20080069901Abstract: To provide a therapeutic agent for metastatic cancer and a cancer metastasis inhibitor which are highly safe and efficaciously treat metastatic cancer and inhibit cancer metastasis, and especially efficaciously treat and inhibit cancer metastasis to bone and liver. There are provided a therapeutic agent for metastatic cancer and a cancer metastasis inhibitor each of which includes a platinum complex having an anticancer activity as an active ingredient. The platinum complex is preferably cisplatin. The therapeutic agent for metastatic cancer is advantageously usable for treating metastatic cancer to bone and/or liver. The cancer metastasis inhibitor is advantageously usable as a cancer metastasis inhibitor for inhibiting metastasis to bone and/or liver. These agents can advantageously further include a bisphosphonate as another active ingredient.Type: ApplicationFiled: December 6, 2005Publication date: March 20, 2008Applicant: TMRC Co. , Ltd.Inventor: Hisao Ekimoto
-
Publication number: 20070191260Abstract: There is provided a novel pyrrole-imidazole polyamide compound for alkylating the specific base sequence of DNA, the polyamide compound being capable of being synthesized through fewer reaction steps than known hybrid molecules and having a combination of a high reactivity in DNA alkylation and the ability to recognize a sequence. Furthermore, there is provided an alkylating agent and a molecule serving as a drug, the alkylating agent and the molecule containing the polyamide compound.Type: ApplicationFiled: March 10, 2005Publication date: August 16, 2007Applicant: Tmrc Co., Ltd.Inventors: Hiroshi Sugiyama, Toshikazu Bando
-
Patent number: 5574828Abstract: A system utilizing a software program used to write other software application programs for the implementation of guideline applications for use in situations where a qualification decision or next course of action determination must be made. The system uses questions with limited choice answers. Data provided in answer to the questions causes a second program application to be automatically generated based on the answers. The second application then elicits responses in an interactive manner. Qualification decisions and courses of action are suggested as an output of the second application. Means are provided for evaluating the reliability of the suggestions based on consistency of answers and fatigue of the user. Means are also provided for editing either application program.Type: GrantFiled: April 28, 1994Date of Patent: November 12, 1996Assignee: TMRCInventors: Robert S. A. Hayward, Michael F. Roizen, David Summerell, Martin Rom